MedTrace Logo

HRQOL in Locally Advanced Thyroid Carcinoma

NCT05824312 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-04-21

No results posted yet for this study

Summary

The purpose of this study was to explore the changes of health-related quality of life (HRQOL) in patients with locally advanced thyroid cancer (LATC) receiving TKI drugs (anlotinib, lenvatinib, etc.).

Conditions

  • Thyroid Cancer
  • Tyrosine Kinase Inhibitor
  • Health Related Quality of Life

Interventions

DRUG

Tyrosine kinase inhibitor drugs.

TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Hui Liu · FujianMedical University Cancer Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-01-31
Completion
2026-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05824312 on ClinicalTrials.gov